Loading…
← CockpitCompetitor Analysis › 688161.SS Shandong Weigao Orthopaedic Device Co., Ltd. Class AOpen in the cockpit ↗

Shandong Weigao Orthopaedic Device Co., Ltd. Class A688161.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Weigao Group's orthopedic implant subsidiary, making joint-replacement, spine and trauma devices.

≈ A Chinese Zimmer Biomet/Stryker OrthopaedicsMomentum neutral 45
Mkt cap
$1.14B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$3.78M
20-day average traded
Fwd P/E
24.9×
forward earnings
ROIC−WACC
+0.2 pp
WACC 7.9%
Hurdle
+15 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥19.32
1D-2.6%
1W-6.5%
1M-12.7%
3M-14.3%
6M-28.7%
YTD-30.8%
1Y-33.4%
ATR %3.4%
52w lowhigh40.9% off high

What Shandong Weigao Orthopaedic Device does

Weigao Group's orthopedic implant subsidiary, making joint-replacement, spine and trauma devices.

Sells implants to hospitals mostly through distributors. China's government bulk-purchase tenders for joint, trauma and spine implants have set prices for much of the market, so winning tender volume matters more than list price. It is a listed subsidiary of Weigao Group, whose hospital relationships it draws on.

In one line: A Chinese Zimmer Biomet/Stryker Orthopaedics.

Products and services

  • Joint replacement implants
  • Spine implants
  • Trauma fixation devices

Customers

  • Orthopedic surgeons/hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Orthopedic implants

What could go right

  • China orthopedic procedure-volume growth

What could go wrong

  • Volume-based procurement price cuts

Moat: narrow (regulatory licence, installed base). Weigao Group's hospital distribution scale supports an established device franchise.

Headquarters: Weihai, Shandong, China · Employees: 1,988

Named competitors

Shandong Weigao Orthopaedic Device at a glance

Size Shandong Weigao Orthopaedic Device (688161.SS) is a China Health Care company (Medical Specialties) with a market value of $1.14B, the 1910th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.32 on 18 Nov 2026.

Performance Over six months the shares fell 28.7%, against -9.9% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue fell 6.0% over the last twelve months (peer median +12.0%); the operating margin is 17.7% (peer median 6.7%).

Valuation It trades at 24.9× forward earnings against a peer median of 23.9× (6th most expensive of 12).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.2 points above its cost of capital (7.9% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 88688161.SS 72
Six months, rebased to 100: Shandong Weigao Orthopaedic Device against the median of its 20 peers (local-currency closes).

Shandong Weigao Orthopaedic Device financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.39BCN¥1.51BCN¥1.44BCN¥1.27BCN¥2.03B
Revenue growth—+5%+14%-38%—
Gross profitCN¥949MCN¥936MCN¥916MCN¥810MCN¥1.52B
EBITDAn/aCN¥384MCN¥327MCN¥175MCN¥726M
Net incomeCN¥239MCN¥269MCN¥224MCN¥112MCN¥601M
Free cash flowCN¥253MCN¥421MCN¥283MCN¥100MCN¥419M
Capital expenditureCN¥43.0MCN¥27.1MCN¥24.3MCN¥43.0MCN¥116M
Total debtCN¥77.2MCN¥80.8MCN¥79.1MCN¥96.4MCN¥55.8M

Quarterly statements and history in the cockpit →

Shandong Weigao Orthopaedic Device competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%300406DRTSTNDMATEC2675214150688050301101688622SIBN688289IRMDNVCRSTAACSTLEUZ600055301021688161.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shandong Weigao Orthopaedic Device is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×300406ATEC2675214150688050IART301101688289STAA688161.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Weigao Orthopaedic Device is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%300406214150688050IART301101IRMDSTAACSTL301021688161.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shandong Weigao Orthopaedic Device is the large dot.

Shandong Weigao Orthopaedic Device competitors and peer comparison

Head to head with its named competitors (688161.SS vs ZBH vs SYK vs 002901.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shandong Weigao Orthopaedic Device 688161.SS$1.14B-29%-6%18%24.9×11.3%
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Double Medical Technology 002901.SZ$2.43B-2%+13%26%24.2×7.6%
Beijing Chunlizhengda Medical Instruments 1858.HK$631M-28%-9%31%8.5×-9.5%

How Shandong Weigao Orthopaedic Device compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Weigao Orthopaedic Device against its 20 peers (data as of 18 Nov 2026)
Measure688161.SSPeer medianRank in peer set
1-month return-12.7%-4.7%7th lowest of 21
6-month return-28.7%-9.9%5th lowest of 20
Distance from 52-week high-40.9%-36.6%9th lowest of 21
Revenue growth (TTM)-6.0%+12.0%3rd lowest of 19
Operating margin17.7%6.7%7th highest of 20
Forward P/E24.9×23.9×6th most expensive of 12
Growth the price implies (Req g, 7 yrs)11.3%9.6%5th most demanding of 11
Growth delivered (Del g)-3.5%+11.0%lowest of 11
Hurdle (Req g minus delivered)+14.8 pp-1.5 pp4th most demanding of 11
ROIC minus cost of capital+0.2 pp-2.5 pp8th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%

Questions

Who are Shandong Weigao Orthopaedic Device's main competitors?
Named competitors: Zimmer Biomet (ZBH), Stryker (SYK), Double Medical Technology (002901.SZ), Chunli Medical (1858.HK). The cockpit's measured peer set (industry) also includes Beijing Strong Biotechnologies (300406.SZ), Alpha Tau Medical (DRTS), Tandem Diabetes Care (TNDM), Alphatec (ATEC), Freenome (FRNM), Shenzhen Edge Medical (2675.HK).
Is Shandong Weigao Orthopaedic Device expensive compared with its peers?
On forward p/e it trades at 24.9× against a peer median of 23.9×, 6th most expensive of 12 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shandong Weigao Orthopaedic Device stock performed?
Over six months to 18 Nov 2026 the shares returned -28.7% against -9.9% for the median peer; over one year -33.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.